Aptose Biosciences, Inc. (APTO)
| Market Cap | 240.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.94M |
| Shares Out | 88.94M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $2.70 |
| Previous Close | $2.65 |
| Change ($) | 0.05 |
| Change (%) | 1.89% |
| Day's Open | 2.61 |
| Day's Range | 2.59 - 2.76 |
| Day's Volume | 583,735 |
| 52-Week Range | 2.55 - 7.27 |
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlyi...
Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or ref...
SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...
These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyin...
- Conference call and webcast at 4:30 pm EDT today -
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly...
Aptose Biosciences Inc. (NASDAQ: APTO) shares traded higher after the company's release of fourth-quarter results Tuesday. The stock gained 66.21% in Wednesday's regular session, closing at $6.10.
The company reported very encouraging results from an early-stage study.
APTO stock is rocketing this morning as the company releases some encouraging research details alongside its Q4 earnings report. The post APTO Stock: Why Aptose Biosciences Is Rocketing Higher Today app...
- Conference call and webcast at 5pm EDT today -
George Melko, Pharm.D. joins as Vice President, Regulatory Affairs
SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...
Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.
Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lower doses of...
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th,...
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers
Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.
Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is unclear whet...
Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level
Abstracts Accepted for Presentation Abstracts Accepted for Presentation
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...
Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.
Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg
SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under...
SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under...
Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
APTO's lead candidate, CG-806, is due for important updates in 4Q2020.
SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlyi...
Aptose has recently raised more cash, and looks set for its foreseeable clinical trial needs.
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl...
Dilution is on the way.
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public offer...
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML
Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies
SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therape...
Aptose Biosciences' (APTO) CEO William Rice on Q1 2020 Results - Earnings Call Transcript
SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents t...
Data from patients at first two dose levels; Phase 1a/b study is ongoing Data from patients at first two dose levels; Phase 1a/b study is ongoing
Aptose Riding Higher As The Street Starts Paying Attention
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the t... [Read more...]
| Industry Biotechnology | Founded 1986 |
| CEO William Rice | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol APTO |
Analyst Forecasts
According to 8 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.72, which is an increase of 74.81% from the latest price.